KSQ-004EX
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for KSQ-004EX, covering 2026-04-16 to 2026-04-16. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors [Phase 1, Phase 2]